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Purpose: Management of metastatic disease in oncology includes monitoring of therapy 
response principally by imaging techniques like CT-Scan. In addition to some limitations, the 
irruption of liquid biopsy and its application in personalized medicine has encouraged the 
development of more efficient technologies for prognosis and follow-up of patients in 
advanced disease. 
Methods: PrediCTC constitutes a panel of genes for the assessment of Circulating Tumor 
Cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency 
compared to CT-Scan for the evaluation of early therapy response in a multicenter 
prospective study. In this work, we designed and developed a technology transfer strategy 
to define the market opportunity for an eventual implementation of PrediCTC in the clinical 
practice. 
Results: This included the definition of the regulatory framework, the analysis of the 
regulatory roadmap needed for CE mark, a benchmarking study, the design of a product 
development strategy, a revision of intellectual property, a cost-effectiveness study and an 
expert panel consultation. 
Conclusion: The definition and analysis of an appropriate technology transfer strategy and 
the correct balance among regulatory, financial and technical determinants are critical for 
the transformation of a promising technology into a viable technology, and for the decision 









Metastasis represents the most devastating event in oncology. The presence of locoregional 
and distant metastasis represents a contraindication to surgery and radiotherapy, is 
associated with chemotherapy resistance, and is responsible for more than 90% of cancer 
related deaths. Colorectal cancer (CRC) is the third most common cancer worldwide being 
responsible for 8% of cancer-related deaths in men and 9% in women [1]. About 80% of 
patients with CRC present with localized or locoregional and resectable disease at 
diagnosis, with a 90% five-year relative survival rate in localized disease and 70% with 
regional dissemination. Five-year survival rate drops to 13% for the remaining 20% patients 
presenting with distant metastasis at diagnosis [1]. In addition, the risk of relapse also 
depends on the pathological stage of the primary tumor (30% for stage II and 50% for stage 
III) and is higher within the first two years after surgery. Liver constitutes the main metastatic 
organ in CRC. Although less frequent, abdominal lymph nodes, peritoneum and lungs are 
also affected by CRC dissemination [2]. 
 
The current management of unresectable metastatic CRC consists of systemic 
chemotherapy involving various agents, alone or in combination. The choice of therapy is 
based on several factors, namely the performance status (PS) of patients and the goals of 
treatment. Also, clinical management of metastatic disease is an example of a 
multidisciplinary task involving oncologists, surgeons and radiologists. More effective 
therapeutic regimens together with improved surgical and radiological procedures have 
nowadays significantly increased stage IV patient’s survival rates. Standard treatment of 
metastatic CRC is based on the use of fluoropyrimidines (fluorouracil or capecitabine), either 
in monotherapy or combined with oxaliplatin/irinotecan and targeted drugs (bevacizumab, 
cetuximab, panitumumab, regorafenib and aflibercept). In patients with good PS and without 
contraindications, a combination therapy is recommended, whereas a monotherapy should 
be preferred for elderly patients or those with significant comorbidities or in poor clinical 
condition [3]. Nevertheless, and despite the important improvements in mCRC therapeutic 
strategies, response rates are still low (30–60%), meaning that a high number of patients 
will not benefit from the therapy, but will suffer toxicity-related side effects. 
 
Response to chemotherapy is monitored using imaging, usually by computed tomography 
(CT) scans, performed regularly and usually every 12 weeks during the course of a given 
therapy. Disease progression should be confirmed with radiographic testing (eg, CT scan) 
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or a biopsy before changing treatment. Morphologic measurement of change in tumor size 
helps assess therapeutic effectiveness by the use of the Response Evaluation Criteria in 
Solid Tumors (RECIST) and their modified criteria (version 1.1) during cytotoxic 
chemotherapy. CT scan data can be quantified and processed to provide accurate and 
reliable anatomic information about not only tumor shrinkage or growth but also progression 
of disease by identifying either growth in existing lesions or the development of new lesions. 
However, there are limitations in the evaluation of tumor response when employing 
conventional criteria alone, like in detection of peritoneal tumor implants, soft hypodense 
tissue material associated with chemotherapy, or to adequately correlate with clinical 
outcomes when assessing treatments that operate via other mechanisms different from 
tumor size, including molecular targeted treatments and immunotherapies [4]. In addition, 
imaging methods cannot be repeatedly performed due to risks for patient health derived 
from radiation overexposure. In a new era of molecular-targeted cancer therapies, the need 
of more accurate, specific and early response-assessment methods continuously increases. 
Early predictive markers such as KRAS mutation status have shown to be effective for 
therapy-based patient stratification, and biomarkers like carcinoembrionic antigen (CEA) are 
also an indicative tool for treatment effectiveness in mCRC patients, but none of them are 
conclusive as markers for therapy monitoring. 
 
Metastatic spreading is tightly associated with the propagation of aggressive tumor cells, 
which successfully escape primary tumors reaching the bloodstream and thus any virtual 
secondary location [5]. The detection of these circulating tumor cells (CTCs) has 
demonstrated a clinical prognostic value in patients bearing metastatic tumors, showing 
reduced survival rates when the number of CTCs met a certain threshold. Using the 
CellSearch system (Veridex), the unique platform CTC enumeration cleared to date by the 
American Food and Drug Administration (FDA), it has been reported that the presence of 3 
or more CTCs per 7.5 mL of blood in mCRC patients predicted poor patient outcome at 
baseline, e.g., before treatment [6]. Apart from the CellSearch system, other approaches 
like density gradient centrifugation, filtration or the more recent inertial focusing separation 
or dean flow fractionation methods, have been proposed as alternatives for CTC isolation 
from blood [7]. In addition, changes on CTC numbers along treatment have shown a 
correlation with therapy effectiveness [8]. Thus, CTC analysis represents an attractive 
candidate for liquid biopsy in cancer, although the immediate future challenge relies on 




Preliminary clinical studies: 
In a previous work [10], we reported the identification of PrediCTC, a multimarker CTC 
detection panel that effectively predicted patient outcome before treatment, and provided 
information about early therapy effectiveness. This multimarker model accurately detected 
CTC in metastatic CRC (mCRC) patients, based on expression levels of a six-gene panel 
of tissue specific and Epithelial to Mesenchymal Transition (EMT)-related markers (GAPDH, 
VIL1, CLU, TIMP1, LOXL3 and ZEB2), and CD45 as an indicator of unspecific cell isolation. 
This model effectively predicted prognosis, but more importantly it demonstrated an early 
predictive clinical utility, with an increased sensibility when compared to routine clinical 
imaging methods. This initial study was conducted in a total of 50 mCRC patients recruited 
at the University Clinical Hospital of Santiago de Compostela, with the presence of 
measurable Stage IV CRC, PS equal or less than 2 (based on the Eastern Oncology 
Cooperative Group (ECOG) scale), and at initiation of a first systemic chemotherapy line, as 
inclusion criteria. After EpCAM-based CTC immunoisolation and RNA extraction, gene 
expression levels of CTC-markers, accurately classified patients with high or low levels of 
CTC, showing a prognostic value. PrediCTC also demonstrated utility to assess therapy 
response after only one cycle of chemotherapy, with a mean progression-free survival (PFS) 
of 12.70 months for responders vs. 6.75 months for non-responders (p=0.004), and an 
overall survival (OS) of 24.26 vs. 13.05 months (p=0.007). These results were further 
confirmed in an independent prospective multicenter study with 43 mCRC patients recruited 
in four hospitals from the Galician health system (SERGAS). Briefly, PrediCTC 
demonstrated an improved sensibility at detection of patient responders after only one cycle 
of chemotherapy compared to CT-Scan performed at third cycle of therapy (60% PrediCTC 
versus 17% CT scan), in detriment to a reduction in specificity from 98% by CT scan to 90% 
with PrediCTC. This mainly resulted in an improved ability to identify real non-responders 
(86% negative predictive value), which is a major clinical necessity for the oncologists in 
order to decide moving from a non-effective treatment towards a potentially useful therapy 
as soon as after one cycle of chemotherapy. Overall, and in addition to the accessibility of 
liquid biopsy and of the clinical information on patient responsiveness, when compared to 
standard CT scan performed after three cycles of chemotherapy, PrediCTC demonstrated 





Figure 1: Schema of PrediCTC workflow compared to CT-Scan: while CT-Scan monitors patient 
response after the third cycle of chemotherapy, PrediCTC evaluates the responsiveness of the 
therapy after the first cycle of treatment. In addition to the early assessment and the accessibility of 
the blood sample, PrediCTC results in an improved sensibility compared to CT-Scan, with an 
affordable reduction in specificity. 
 
Objective of the study: 
These preliminary studies suggested a potential clinical utility of PrediCTC for early therapy 
response monitoring in advanced CRC patients, with an improved sensibility compared to 
standard CT scan. We thus aimed to design and develop a technology transfer strategy to 
define the market opportunity for an eventual implementation of PrediCTC in the clinical 
practice. This included the definition of the regulatory framework, the analysis of the 
regulatory roadmap needed for CE mark, a benchmarking study, the design of a product 
development strategy, a revision of intellectual property (IP), a cost-effectiveness study and 
an expert panel consultation.  
 
Definition of the regulatory framework for PrediCTC: 
The analysis of the regulatory requirements for this technology determined that PrediCTC is 
classified as an in vitro diagnostic (IVD) kit as per the In vitro Diagnostic Medical Devices 
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Directive 98/79/EC (IVDD), that must follow an autocertificate evaluation for CE mark 
according to a declaration of conformity. This must be accompanied by the technical file 
including a complete description of the product, all the documentation related to the quality 
system, a risk analysis, and the corresponding reports describing the evaluation of 
performance of the technology, its stability, labelling and instructions for use. In addition, the 
manufacturer must fulfil the principles of quality guarantee including the organization 
structure and responsibilities, the adequate processes of fabrication and control of the 
quality of the production, and the appropriate implementation of the quality system controls. 
This quality system must be validated by a notified body. 
 
Benchmarking analysis of PrediCTC technology: 
Two main technologies have been identified as similar IVD products approved for 
commercialisation and potential competitors for PrediCTC: CellSearch Test from Veridex, 
mentioned above, and AdnaTest from Qiagen. The CellSearch Test (Janssen Diagnostics, 
LLC; https://www.cellsearchctc.com) is the first and only clinically validated, FDA-cleared 
test for capturing and enumerating CTCs to help inform clinical decision-making. The 
evaluation of CTCs by CellSearch allows patient prognosis assessment and is predictive of 
progression-free survival and overall survival. CellSearch is a semi-automated technology 
that combines immunoisolation of EpCAM positive epithelial cells from peripheral blood, with 
the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and 
cytokeratins 8, 18+, and/or 19+). 
 
Although the relative automatization level of sample processing and the accessibility to 
reproducible interpretation of data permits a reasonable degree of standardization of studies 
for clinical validation, the strict criteria for CTC definition and the absence of a product 
actualization strategy since the first studies in advanced breast [12], colorectal (7) and 
prostate [13] cancer and its commercialisation almost ten years ago, is limiting the use of 
this technology in the clinical routine. 
 
AdnaTest Colon Cancer (http://www.qiagen.com) is a CE marked product for the detection 
of CTCs in colorectal cancer patients. Similar to PrediCTC, AdnaTest combines a first step 
of in vitro CTC enrichment from cancer patients’ blood samples using magnetic bead 
conjugated antibodies optimized for this cancer type, and a second step where the isolated 
mRNA is transcribed into cDNA that can be amplified in a following multiplex-PCR detection 
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step, analysing the tumor associated gene expression of a variety of relevant tumor markers. 
Compared to CellSearch, the combination of a variety of selection markers for CTC 
enrichment (tumor-associated antibodies) and a set of molecular tumor markers (EpCAM, 
CEA and EGFR) improves the sensibility of CTC detection and quantification. Particularly, 
this allows taking into account CTCs heterogeneity, which prevents for false negative and 
positive results due to either marker expression in normal blood cells or gene expression 
changes during chemotherapy. Also similar to PrediCTC, Adnatest includes a first kit for the 
isolation of CTCs and the subsequent extraction of mRNA from human whole blood, and 
second RT-PCR kit for detection of colon cancer-associated gene expression in enriched 
tumor cells. To date, limited studies with clinical evidences have demonstrated the utility of 
AdnaTest technology at the clinical setting [14]. 
 
Product development strategy for PrediCTC: 
The development plan for PrediCTC has been defined following the international standards 
for quality management systems for medical devices (ISO 13485) and for performance 
evaluation of in vitro diagnostic medical devices (ISO 13612). First, the design of the 
PrediCTC diagnostic IVD kit, including the physical prototype and the clinical protocol for the 
processing and management of the samples, was preferably defined as a “minimumm viable 
kit (MVK)” containing all those components considered as “know how”; the remaining 
elements provided out of the kit, to facilitate the manufacture, reduce costs and diminish 
stability risks. 
 
Second, the PrediCTC diagnostic IVD kit must be validated through a scientific validity and 
a performance evaluation (Figure 2). The scientific validity containing all the  information on 
the validity of CTC evaluation for the follow-up of treatment of patients with metastatic 
colorectal cancer and on the limitations of PrediCTC, includes information from equivalent 
IVD products as CellSearch and ADNAtest, from the literature and opinion documents, and 
from clinical data obtained with PrediCTC. The performance evaluation corresponding to a 
new test must follow an analytical and a clinical evaluation. The analytical evaluation 
demonstrates the efficacy of the technology and includes data on sensibility and specificity, 
compared to the CT scan as standard reference. The clinical evaluation aims to evaluate 
the efficacy of PrediCTC in clinical practice conditions. This includes the target population, 
the characterisation and processing of the samples, the characterisation of the analyte and 
its detection, the reactives and the equipment. For this, a new multicentric, prospective, 
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observational and longitudinal study in a 150-300 patient population performed in 3-6 
months should provide conclusive data on overall percent assessment. Finally, the 
estimated timing and costs for the development plan are one year and approximately 300k 
euros, including registry of CE mark and licence. 
 
 
Figure 2: Performance evaluation of PrediCTC technology. 
 
Intellectual Property analysis: 
PCT/EP2015/056649 application provides a panel of biomarkers with predictive value for 
therapy effectiveness in patients suffering from metastatic colorectal cancer. In particular, 
this patent application provides a method for determining progression free survival and 
overall survival in response to therapy in mCRC patients by assessing the expression level 
of at least one gene selected from the group consisting of LOXL3, ZEB2, GAPDH, VIL1, 
TIMP1, CLU and TLN1 in the circulating tumor cells of a blood sample taken from the patient 




In the international phase of the PCT, the Written Opinion raised a number of objections, in 
particular a unity of invention objection as well as a lack of inventive step objection to all 
those claims linked by the presence of LOXL3, with the exception of those claims referring 
to the specific combination of the following seven genes: GAPDH, VIL1, TIMP1, CLU, TLN1, 
LOXL3 and ZEB2. Therefore, a priori, the protection conferred by PCT/EP2015/056649 is 
limited to the combination of GAPDH, VIL1, TIMP1, CLU, TLN1, LOXL3 and ZEB2. Such 
protection is certainly limited. 
 
In addition, PCT/EP2015/056649 is silent about the possibility of using kits or devices for 
implementing the method disclosed therein. Lastly, in case these limitations can be 
overcome, the commercialization opportunity of a PrediCTC kit or device must be 
determined by an evaluation of any possible intellectual property hurdles to said 
commercialization through a freedom to operate analysis. 
 
Cost-effectiveness evaluation: 
This section on economic evaluation summarizes the estimated cost-effectiveness of 
PrediCTC, as a multimarker panel from circulating tumor cells developed to assess the 
chemotherapy response, versus CT scan, in the follow up of first-line treatment response in 
patients with un-resectable mCRC, described in [15]. 
Based on Barbazan et al., 2014 and ESMO (European Society for Medical Oncology) 
guidelines, a Markov model has been developed with transition probabilities being 
established by free progression survival and overall survival results from the main clinical 
trials for the different treatments received by mCRC patients, together with utilities and 
adverse events rates [15]. As well, direct and indirect resources use and unitary cost data 
were obtained from published studies, drugs technical files, and regional health systems’ 
prices. 
 
Base case analysis showed savings in all costs, and probabilistic sensitivity analysis results 
confirmed the data from the base case scenario: PrediCTC is more efficient than CT Scan 
with a probability of 91.20% to be cost-effective at a 30,000 €/QALY threshold. CT Scan 
option achieves a higher utility because the model is prepared to assign lower utilities to 
patients as they progress through chemotherapy lines. Finally, from the Spanish societal 
perspective PrediCTC results a cost-effectiveness option as it allows identifying patients that 
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are not getting benefits from therapy in mCRC and therefore to avoid side effects and costs 
in those who are non-responders. 
 
Expert panel consultation: 
We finally explored the viability of PrediCTC in the clinical practice by exposing PrediCTC 
technology and its preliminary clinical data to a panel of expert Spanish oncologists. Three 
main concerns were identified by the experts for the implementation of PrediCTC in the 
clinical routine at the medical oncology departments in hospitals of the Spanish healthcare 
system: first, the likelihood that PrediCTC end up by substituting CT scan in the follow-up of 
mCRC patients, at least for the first line of chemotherapy, is not realistic as the images of 
the tumor lesions are necessary for the evaluation of an eventual surgical treatment. This 
would imply a coexistence of PrediCTC and the CT scan, with complementary information, 
as a more reasonable although less cost-effective scenario for its implementation in the 
oncology practice. The validation of PrediCTC panel in more advanced CRC therapy lines 
could open a more favorable scenario where CT scan could be effectively replaced by liquid 
biopsy, with quality-of-life as main outcome. 
 
Second, the competitive advantage of PrediCTC faced to the two technologies already in 
the market, CellSearch and AdnaTest, should be based not only in the real-time 
quantification of the CTCs in mCRC patients allowing the assessment of therapy response, 
but on additional information providing, for example, clues for the selection of the alternative 
and more efficient therapeutic regimen. In addition, the irruption of ctDNA-related 
technologies, with an apparent more evident applicability in clinical routine, raises a new 
scenario in which the competitiveness of CTC could be compromised; in this sense, and 
although the utility of the CTC analysis remains clear and probably the technologies based 
on ctDNA and CTC ends up being complementary in the clinical setting, so far there are 
uncertainties [16]. 
 
Third, the implementation of PrediCTC in the clinical routine, although favored by the 
minimally invasive collection of a peripheral blood sample, is limited by their complex and 
time-consuming processing, with approximately eight hours of a specialized technician for 
the immunoisolation of CTCs, RNA extraction, pre-amplification and RT-q-PCR for 
PrediCTC panel and interpretation and report of data. In addition, the number of mCRC 
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PrediCTC represents an attractive example of precision medicine, demonstrating the 
potential of liquid biopsy in the management of patients in oncology. The competitive 
advantage of PrediCTC versus the CT scan as the standard technique in monitoring of 
patients has been demonstrated by the preliminary clinical data in a global cohort of 93 
mCRC patients, effectively classifying them in responders and non-responders after only 
one cycle of chemotherapy, with a minimally invasive blood sample, and with an improved 
sensibility. The reduction in toxic secondary effects and costs of inefficacious cycles of 
chemotherapy represent the principal benefits of PrediCTC. The regulatory roadmap is clear 
and reasonable in terms of costs and time to market. Nevertheless, the limitations in the IP 
protection and in the implementation in the clinical practice represent two major concerns to 
effectively translate PrediCTC into the market. A different commercialization strategy, based 
on know-how and a centralized laboratory, and more advanced third/forth lines of 
chemotherapy as a different target population where PrediCTC could demonstrate an 
additional benefit in terms of quality of life, are potential alternatives for the efficient transfer 
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1. A method for determining the outcome of a subject suffering from metastatic colorectal 
cancer (mCRC) and/or the effectiveness of a therapy administered to said subject that 
comprises the steps of: 
a) taking a first follow-up blood sample from the subject after having been administered at 
least one therapy cycle; 
b) assessing the expression level of at least one gene selected from the set of genes of the 
group of LOXL3, ZEB2, GAPDH, VIL1, TIMP1, CLU and TLN1 in the CTCs of the 
blood sample; 
c) classifying the expression level of the selected gene, or of each one of the set of genes 
selected for being analysed, in the CTCs of the blood sample as "high" when it is 
higher than a reference cutoff value of the expression level of said gene and "low" 
when it is equal or lower than said reference cutoff value; 
d) classifying the blood sample as 
i. "low-CTC", if the expression level of the selected gene in CTCs is low or, when more 
than one gene of the above mentioned set of genes is being analysed, if the 
expression level in CTCs of more than a half of said analysed genes is low; 
ii. "high-CTC", if the expression level of the selected gene in CTCs is high or, when 
more than one gene of the above mentioned set of genes is being analysed, if the 
expression level in CTCs of at least one half of said analysed genes is high; 
e) assessing the effectiveness of the administered therapy by classifying the subject as: 
i. "non responder" to the therapy, if the subject is "high-CTC" for the analysed follow-up 
blood sample, and 
ii. "responder" to the therapy, if the subject is "low-CTC" for the analysed follow-up blood 
sample; 
f) optionally, taking a second or additional follow-up blood samples from the subject after 
having been administered a therapy cycle subsequent to the therapy cycle already 
administered when the first follow-up sample was taken and repeating steps b) to e) 
with said second or subsequent follow-up sample to confirm the previous 
assessment of therapy effectiveness; 
g) additionally, or alternatively to steps e) and f), predicting the outcome of the subject at a 
time point of therapy course by classifying the subject as a "high risk" subject when 
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the blood sample taken at that time point is "high-CTC", and as a "low risk" subject 
when the blood sample taken at that time point is "low-CTC". 
2. The method according to claim 1, wherein the expression level of at least two, three, four, 
five, six or all the seven genes of the group of LOXL3, ZEB2, GAPDH, VIL1, TIMP1, CLU 
and TLN1 is determined and classified in steps a) and b) and used for classifying the blood 
sample and the patients in step c) and d) and e) and, when carried out, in step e) and/or f). 
3. The method according to claim 1 or 2, wherein LOXL3 and/or ZEB2 is selected for 
determining and classifying its expression level in steps a) and b) and used for classifying 
the blood sample and the patients in step c) and d) and, optionally, in step e) and, when 
carried out, in step e) and/or f). 
4. The method according to claim 2 and 3, wherein the expression level of at least the two 
genes LOXL3 and VIL1 is determined and classified in steps a) and b) and used for 
classifying the blood sample and the patients in step c) and d) and, when carried out, in step 
e) and/or f). 
5. The method according to claim 4, wherein the expression level of at least the three genes 
LOXL3, VIL1 and CLU is determined and classified in steps a) and b) and used for 
classifying the blood sample and the patients in step c) and d) and, when carried out, in step 
e) and/or f). 
6. The method according to claim 5, wherein the expression level of at least the four genes 
LOXL3, VIL1, CLU and GAPDH is determined and classified in steps a) and b) and used for 
classifying the blood sample and the patients in step c) and d) and, when carried out, in step 
e) and/or f). 
7. The method according to any one of claims 1 to 3, wherein six genes of the group of 
GAPDH, VIL1, TIMP1, CLU, TLN1, LOXL3 and ZEB2 are selected for carrying out the steps 
of the method and the six genes are: GAPDH, VIL1, TIMP1, CLU, LOXL3 and ZEB2, or 
GAPDH, VIL1, CLU, TLN1, LOXL3 and ZEB2, or, GAPDH, VIL1, TIMP1, TLN1, LOXL3 and 
ZEB2, and wherein the blood sample to be classified in step c) is classified as "low-CTC" 
when the expression level of at least four genes of the set of analysed genes is low, and 
"high-CTC" when the expression level of three or more genes of the set of analysed genes 
is high. 
8. The method according to any one of claims 1 to 3, wherein the seven genes of the group 
of GAPDH, VIL1, TIMP1, CLU, TLN1, LOXL3 and ZEB2 are selected for carrying out the 
steps of the method, and wherein the blood sample to be classified in step c) is classified as 
"low-CTC" when the expression level of at least four genes of the set of analysed genes is 
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low, and "high-CTC" when the expression level of three or more genes of the set of analysed 
genes is high. 
9. The method according to any one of claims 1 to 8, wherein a previous blood sample is 
taken from the subject before having administered the therapy cycle that has been 
administered when the first follow-up sample is taken, and steps b) to e) and, optionally, f), 
and, optionally or alternatively to steps e) and f), step g), are also performed in said previous 
blood sample. 
10. The method according to claim 9, wherein step f) of confirmation is carried out when the 
subject is "low-CTC" for the follow-up blood sample considered in step d) and "high-CTC" 
for the immediately previous sample. 
11. The method according to claim 10, wherein the follow-up sample considered in step d) 
is the first follow-up blood sample and the immediately previous sample is the baseline 
sample taken before the start of the therapy. 
12. The method according to any one of claims 9 to 11, wherein step g) is carried out for 
predicting the outcome of the patient before therapy, on a blood sample which is the baseline 
sample taken before the start of the therapy. 
13. The method according to any one of claims 1 to 11, wherein the administered therapy 
to be assessed is chemotherapy 
14. The method according to claim 13, wherein the chemotherapy to be assessed comprised 
the administration of at least one fluoropyrimidine (fluorouracil or capecitabine) alone or in 
combination with oxaliplatin or irinotecan and/or with anti-EGFR or anti-VEGF antibodies. 
15. The method according to claim 13 or 14, wherein the first follow-up blood sample is 
taken before therapy cycle 2 or 4 weeks after the start of therapy. 
16. The method according to claim 14 or 15, wherein step f) is carried out and a second 
follow-up blood sample is taken before therapy cycle 3 or 16 weeks after the start of therapy. 
17. The method according to any one of the preceding claims, wherein the expression level 
of each analysed gene is normalized with regard to the expression level of a reference gene. 
18. The method according to claim 17, wherein the reference gene is CD45. 
19. The method according to any one of the preceding claims, wherein the blood samples 
are enriched in CTCs by using a immunoaffinity technique based on anti-EpCAM antibodies. 
20. The method according to any one of the preceding claims, wherein the expression level 
of each gene in each sample is assessed by quantifying the level of its corresponding mRNA 
in said sample. 
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21. The method according to any one of the preceding claims, wherein each reference cutoff 
value that is used in step c) has been determined in a statistical study with mCRC patients 
as the 75% percentile value of the expression level of the corresponding gene at the time 
point of the therapy course wherein the blood sample to be classified has been taken. 
22. The method according to any one of the preceding claims, wherein the assessment is 
complemented with the results of an imaging technique such a CT colonography and/or with 
a monitoring technique based on the determination of a biomarker in serum such as CA-125 
or CEA. 
